The stock of Lineage Cell Therapeutics Inc (AMEX: LCTX) has decreased by -3.66 when compared to last closing price of 0.50.Despite this, the company has seen a loss of -9.61% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-10 that Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Ioana Hone – Head of Investor Relations Brian Culley – Chief Executive Officer Jill Howe – Chief Financial Officer Conference Call Participants Jack Allen – Baird Joseph Pantginis – H.C. Wainwright Michael Okunewitch – Maxim Group Mayank Mamtani – Riley Securities Albert Lowe – Craig-Hallum Sean McCutcheon – Raymond James Operator Thank you for standing by.
Is It Worth Investing in Lineage Cell Therapeutics Inc (AMEX: LCTX) Right Now?
Additionally, the 36-month beta value for LCTX is 1.29. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for LCTX is 227.36M and currently, short sellers hold a 9.69% ratio of that float. The average trading volume of LCTX on March 19, 2025 was 1.79M shares.
LCTX’s Market Performance
LCTX’s stock has seen a -9.61% decrease for the week, with a -30.68% drop in the past month and a -7.37% fall in the past quarter. The volatility ratio for the week is 6.86%, and the volatility levels for the past 30 days are at 8.37% for Lineage Cell Therapeutics Inc The simple moving average for the last 20 days is -15.34% for LCTX’s stock, with a simple moving average of -38.62% for the last 200 days.
Analysts’ Opinion of LCTX
Many brokerage firms have already submitted their reports for LCTX stocks, with Craig Hallum repeating the rating for LCTX by listing it as a “Buy.” The predicted price for LCTX in the upcoming period, according to Craig Hallum is $4 based on the research report published on August 20, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see LCTX reach a price target of $5. The rating they have provided for LCTX stocks is “Outperform” according to the report published on November 02nd, 2022.
B. Riley Securities gave a rating of “Buy” to LCTX, setting the target price at $4 in the report published on June 14th of the previous year.
LCTX Trading at -20.21% from the 50-Day Moving Average
After a stumble in the market that brought LCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.08% of loss for the given period.
Volatility was left at 8.37%, however, over the last 30 days, the volatility rate increased by 6.86%, as shares sank -33.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.47% lower at present.
During the last 5 trading sessions, LCTX fell by -9.61%, which changed the moving average for the period of 200-days by -48.20% in comparison to the 20-day moving average, which settled at $0.5690. In addition, Lineage Cell Therapeutics Inc saw -4.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LCTX starting from BROADWOOD PARTNERS, L.P., who purchase 7,894,737 shares at the price of $0.76 back on Jan 27 ’25. After this action, BROADWOOD PARTNERS, L.P. now owns 49,560,992 shares of Lineage Cell Therapeutics Inc, valued at $6,000,000 using the latest closing price.
Howe Jill Ann, the Chief Financial Officer of Lineage Cell Therapeutics Inc, purchase 15,000 shares at $0.59 during a trade that took place back on Nov 26 ’24, which means that Howe Jill Ann is holding 25,500 shares at $8,850 based on the most recent closing price.
Stock Fundamentals for LCTX
Current profitability levels for the company are sitting at:
- -2.26 for the present operating margin
- 0.95 for the gross margin
The net margin for Lineage Cell Therapeutics Inc stands at -1.96. The total capital return value is set at -0.22. Equity return is now at value -26.25, with -17.37 for asset returns.
Based on Lineage Cell Therapeutics Inc (LCTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -9.19.
Currently, EBITDA for the company is -21.48 million with net debt to EBITDA at 2.07. When we switch over and look at the enterprise to sales, we see a ratio of 7.02. The receivables turnover for the company is 14.89for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.65.
Conclusion
In conclusion, Lineage Cell Therapeutics Inc (LCTX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
